

A Conversation with the Investigators: Metastatic Castration-Resistant Prostate Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following outcomes was included in the results of the CARD trial evaluating cabazitaxel versus either of the androgen receptor-targeted agents (ARTAs) abiraterone acetate or enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC) who had previously received docetaxel and experienced disease progression within 12 months while receiving a different ARTA?
 - a. No difference in overall survival (OS) between the treatment arms
 - b. Improvement in OS with cabazitaxel**
 - c. Improvement in OS with an ARTA
2. The Phase III PROfound trial evaluating olaparib versus physician's choice of enzalutamide or abiraterone acetate for mCRPC reported an improvement in which of the following parameters with olaparib in cohort A, patients with alterations in BRCA1/2 and ATM?
 - a. Radiographic progression-free survival (rPFS) only
 - b. OS only
 - c. Both rPFS and OS**
 - d. Neither rPFS nor OS
3. The Phase III VISION trial evaluating standard therapy with or without ¹⁷⁷Lu-PSMA-617 for men with previously treated PSMA-positive mCRPC demonstrated which of the following outcomes with the addition of ¹⁷⁷Lu-PSMA-617?
 - a. Improvement in rPFS only
 - b. Improvement in OS only
 - c. Lower rate of bone marrow suppression only
 - d. Improvement in rPFS and OS and a higher rate of bone marrow suppression**
 - e. No improvement in rPFS or OS and a lower rate of myelosuppression
4. The ongoing Phase III CONTACT-02 trial is investigating which combination regimen versus a second novel hormonal therapy for patients with mCRPC who have previously received 1 novel hormonal therapy?
 - a. Nivolumab/ipilimumab
 - b. Cabozantinib/atezolizumab**
 - c. Olaparib/nivolumab
 - d. Rucaparib/atezolizumab